Guardant Health Inc at Canaccord Genuity Growth Conference (Virtual) Transcript
Hi. Welcome to the 40th Annual Canaccord Genuity Global Growth Conference. I'm Max Masucci, lead diagnostics analyst here at Canaccord. Today, I'm pleased to be joined by Guardant Health, one of the most transformative companies in health care and the market leader in blood-based liquid biopsy test for therapy selection.
Last Friday, Guardant achieved a milestone that we consider a landmark event in the precision medicine space when its Guardant360 test became the first FDA-approved liquid biopsy that is clinically and analytically validated for all solid tumor cancers. Guardant is just scratching the surface in a $50 billion-plus U.S. market and has additional shots on goal and disease monitoring and early cancer screening. So I'm pleased to welcome back CEO, Helmy Eltoukhy. Thanks again for joining us this year.
Thank you for having me, Max.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |